D-0514-2026 Class II Ongoing

Recalled by Ajanta Pharma Ltd. — Aurangabad

FDA drug recall D-0514-2026 was initiated by Ajanta Pharma Ltd. on Apr 29, 2026 and is designated Class II. Reason for recall: CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals. The recall status is ongoing. Affected quantity: 312,894 packs.

Recall details

Product Type
Drugs
Report Date
May 13, 2026
Initiation Date
Apr 29, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
312,894 packs

Product description

Duloxetine Delayed-Release Capsules, 30 mg, Rx Only, a) 90 Capsules, NDC 27241-098-09, b) 30 capsules, NDC 27241-098-03, c) 1000 Capsules, NDC 27241-098-10, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807, Made in India

Reason for recall

CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.

Distribution pattern

Nationwide within U.S

Code information

Lot#: a) PA10774, Exp. May 2026; b) PA10794, PA12174, Exp. Jun 2026; c) PA10804, Exp. Jun-26.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0514-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0514-2026. Report a data issue: hello@regdatalab.com.